US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Actuate Therapeutics Inc

4.41

+0.09002.08%

Post-market: 4.410.00000.00%16:28 EST

Volume:22.10K

Turnover:97.91K

Market Cap:102.50M

PE:-3.66

High:4.53

Open:4.39

Low:4.32

Close:4.32

52wk High:11.99

52wk Low:4.14

Shares:23.24M

Float Shares:9.28M

Volume Ratio:0.31

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2044

EPS(LYR):-3.2588

ROE:-296.04%

ROA:-95.25%

PB:9.37

PE(LYR):-1.35

Loading ...

Overview Company News Filings

Actuate Therapeutics announces plans to expand clinical pipeline

BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers

Actuate Therapeutics Reports Promising Elraglusib Results in Refractory Melanoma

Actuate Therapeutics Inc: Initiation of Phase 1 Portion of Trial Planned in 2H 2026

THOMSON REUTERS

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet Into a Phase 1/2 Clinical Program in Refractory Cancers

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Teva Pharmaceutical (TEVA)

Actuate Therapeutics reports positive Phase 2 pancreatic cancer data

BRIEF-Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing

Actuate Therapeutics says Phase 2 study met primary endpoints

Actuate Therapeutics Reports Phase 2 Trial Success for Elraglusib in Metastatic Pancreatic Cancer

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

Actuate Therapeutics Director Todd Thomson Reports Disposal of Common Shares

BRIEF-Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial

Actuate Therapeutics Reports Positive Phase 1 Results for Elraglusib in Pediatric Ewing Sarcoma and Neuroblastoma

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation

Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer

Actuate Therapeutics Signs $100M Sales Agreement

BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing

Actuate Therapeutics Inc - Enters at the Market Issuance Sales Agreement With B. Riley and Craig-Hallum - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACTU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":4.41,"timestamp":1770411600000,"preClose":4.32,"halted":0,"volume":22102,"hourTrading":{"tag":"盘后","latestPrice":4.41,"preClose":4.41,"latestTime":"16:28 EST","volume":13,"amount":57.33,"timestamp":1770413301977,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.020833333333333297,"floatShares":9280300,"shares":23243328,"eps":-1.204351,"marketStatus":"Market Closed","change":0.09,"latestTime":"02-06 16:00:00 EST","open":4.39,"high":4.525,"low":4.32,"amount":97912.9823,"amplitude":0.047454,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.204351,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":4.32,"postHourTrading":{"tag":"盘后","latestPrice":4.41,"preClose":4.41,"latestTime":"16:28 EST","volume":13,"amount":57.33,"timestamp":1770413301977,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3119284186845451},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":9280300,"roa":"-95.25%","roe":"-296.04%","lyrEps":-3.258828,"volumeRatio":0.3119284186845451,"shares":23243328,"dividePrice":0,"high":4.525,"amplitude":0.047454,"preClose":4.32,"low":4.32,"week52Low":4.14,"pbRate":"9.37","week52High":11.99,"institutionHeld":0,"latestPrice":4.41,"eps":-1.204351,"divideRate":0,"volume":22102,"delay":0,"ttmEps":-1.204351,"open":4.39,"prevYearClose":6.12,"prevWeekClose":4.71,"prevMonthClose":4.71,"prevQuarterClose":6.12,"fiveDayClose":4.71,"twentyDayClose":6.28,"sixtyDayClose":5.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"ACTU","fiscalQuarterEnding":"2025/09","expectedEps":-0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-08-14","symbol":"ACTU","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.3},{"market":"US","date":"2025-05-15","symbol":"ACTU","fiscalQuarterEnding":"2025/03","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1756098000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2026-02-06","current":-3.661723,"percent":0.994709,"low":-9.225925,"twenty":-6.680588,"median":-5.869501,"eighty":-5.163192,"high":-3.930949,"avg":-5.940969,"sd":0.875312,"marketCap":100411176},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-13","current":-6.675228,"twenty":-6.406672,"median":-5.69465,"eighty":-5.089546,"marketCap":168925272},{"date":"2025-06-20","current":-5.806906,"twenty":-6.42894,"median":-5.722554,"eighty":-5.141086,"marketCap":146951253},{"date":"2025-06-27","current":-4.512175,"twenty":-6.410449,"median":-5.697878,"eighty":-5.08284,"marketCap":114186421},{"date":"2025-07-03","current":-5.109147,"twenty":-6.389172,"median":-5.691014,"eighty":-5.046525,"marketCap":129293559},{"date":"2025-07-11","current":-4.791279,"twenty":-6.365148,"median":-5.677284,"eighty":-5.035608,"marketCap":121249498},{"date":"2025-07-18","current":-4.853302,"twenty":-6.320988,"median":-5.645656,"eighty":-4.991444,"marketCap":122819071},{"date":"2025-07-25","current":-5.419262,"twenty":-6.287654,"median":-5.638088,"eighty":-4.976956,"marketCap":137141423},{"date":"2025-08-01","current":-5.620836,"twenty":-6.265937,"median":-5.628589,"eighty":-4.986182,"marketCap":142242535},{"date":"2025-08-08","current":-6.527901,"twenty":-6.287654,"median":-5.632466,"eighty":-4.991444,"marketCap":165196967},{"date":"2025-08-15","current":-6.908485,"twenty":-6.414227,"median":-5.639808,"eighty":-4.995735,"marketCap":170525437},{"date":"2025-08-22","current":-6.442036,"twenty":-6.458702,"median":-5.650353,"eighty":-5.00125,"marketCap":159011858},{"date":"2025-08-29","current":-6.908485,"twenty":-6.483225,"median":-5.670419,"eighty":-5.019908,"marketCap":170525437},{"date":"2025-09-05","current":-7.328709,"twenty":-6.512404,"median":-5.690843,"eighty":-5.033989,"marketCap":180898030},{"date":"2025-09-12","current":-5.859066,"twenty":-6.574176,"median":-5.69465,"eighty":-5.040292,"marketCap":144622132},{"date":"2025-09-19","current":-6.375067,"twenty":-6.549229,"median":-5.726634,"eighty":-5.04517,"marketCap":157358843},{"date":"2025-09-26","current":-6.175411,"twenty":-6.549229,"median":-5.729418,"eighty":-5.051947,"marketCap":152430635},{"date":"2025-10-03","current":-6.212557,"twenty":-6.533707,"median":-5.754096,"eighty":-5.069427,"marketCap":153347511},{"date":"2025-10-10","current":-7.512643,"twenty":-6.537578,"median":-5.770478,"eighty":-5.097386,"marketCap":185438171},{"date":"2025-10-17","current":-7.24334,"twenty":-6.589924,"median":-5.79172,"eighty":-5.109147,"marketCap":178790820},{"date":"2025-10-24","current":-6.732591,"twenty":-6.670885,"median":-5.814177,"eighty":-5.112248,"marketCap":166183775},{"date":"2025-10-31","current":-6.110407,"twenty":-6.6744,"median":-5.859066,"eighty":-5.12,"marketCap":150826102},{"date":"2025-11-07","current":-5.785385,"twenty":-6.670885,"median":-5.869501,"eighty":-5.13638,"marketCap":142803437},{"date":"2025-11-14","current":-5.536933,"twenty":-6.66337,"median":-5.85039,"eighty":-5.154603,"marketCap":136670768},{"date":"2025-11-21","current":-5.868654,"twenty":-6.637844,"median":-5.836285,"eighty":-5.160645,"marketCap":141551867},{"date":"2025-11-28","current":-7.352682,"twenty":-6.647528,"median":-5.86386,"eighty":-5.168486,"marketCap":177346592},{"date":"2025-12-05","current":-7.082858,"twenty":-6.676544,"median":-5.869501,"eighty":-5.172026,"marketCap":170838460},{"date":"2025-12-12","current":-7.150314,"twenty":-6.706669,"median":-5.884194,"eighty":-5.183365,"marketCap":172465493},{"date":"2025-12-19","current":-6.764853,"twenty":-6.718803,"median":-5.896423,"eighty":-5.185781,"marketCap":163168162},{"date":"2025-12-26","current":-6.321572,"twenty":-6.721745,"median":-5.917556,"eighty":-5.189762,"marketCap":152476231},{"date":"2026-01-02","current":-5.897564,"twenty":-6.709975,"median":-5.917556,"eighty":-5.218313,"marketCap":142249167},{"date":"2026-01-09","current":-6.051748,"twenty":-6.706828,"median":-5.918043,"eighty":-5.231645,"marketCap":145968099},{"date":"2026-01-16","current":-5.12664,"twenty":-6.706347,"median":-5.916837,"eighty":-5.218313,"marketCap":123654504},{"date":"2026-01-23","current":-5.251915,"twenty":-6.701519,"median":-5.896423,"eighty":-5.230096,"marketCap":126676137},{"date":"2026-01-30","current":-4.567721,"twenty":-6.691045,"median":-5.884194,"eighty":-5.187481,"marketCap":110173374},{"date":"2026-02-06","current":-4.162986,"twenty":-6.680588,"median":-5.869501,"eighty":-5.163192,"marketCap":100411176}],"updateTime":1770463386973},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605100062","title":"Actuate Therapeutics announces plans to expand clinical pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2605100062","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605100062?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:56","pubTimestamp":1769003766,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patien...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-plans-to-expand-clinical-pipeline-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-announces-plans-to-expand-clinical-pipeline-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2605100988","title":"BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2605100988","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605100988?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:46","pubTimestamp":1769003184,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory CancersJan 21 (Reuters) - Actuate Therapeutics Inc A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2605100983","title":"Actuate Therapeutics Reports Promising Elraglusib Results in Refractory Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2605100983","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605100983?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:45","pubTimestamp":1769003117,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc. has announced plans to advance its elraglusib oral tablet into a Phase 1/2 clinical program targeting refractory cancers, including metastatic melanoma. The program builds on encouraging early clinical evidence of monotherapy activity from a previously completed trial using the IV formulation of elraglusib, which included a complete response lasting over six years in a patient with advanced, refractory BRAFV600E-mutated metastatic melanoma. The upcoming Phase 1 portion, scheduled to begin in the second half of 2026, will assess safety, dosing, and preliminary anti-tumor activity of the oral tablet. The results referenced were from prior studies, and the new research will be conducted and presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL9s2dPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","ACTU","LU2210149790.SGD","SG9999014021.USD","BK4585","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","SG9999014039.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2605100626","title":"Actuate Therapeutics Inc: Initiation of Phase 1 Portion of Trial Planned in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605100626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605100626?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:45","pubTimestamp":1769003107,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0NI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2605006251","title":"Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet Into a Phase 1/2 Clinical Program in Refractory Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2605006251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605006251?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:45","pubTimestamp":1769003107,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2603360244","title":"Analysts Are Bullish on Top Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Teva Pharmaceutical (TEVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603360244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603360244?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:11","pubTimestamp":1768479066,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actuate Therapeutics, Inc. (ACTU – Research Report) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-actuate-therapeutics-inc-actu-teva-pharmaceutical-teva-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-actuate-therapeutics-inc-actu-teva-pharmaceutical-teva-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","BK4139","BK4566","BK4559","BK4137","BK4112","BK4557","LU1983299246.USD","TEVA","LU0029874061.USD","BK4588","BK4584","BK4007","ACTU","LABU","BK4596","LU0128526141.USD","XBI"],"gpt_icon":0},{"id":"2603356529","title":"Actuate Therapeutics reports positive Phase 2 pancreatic cancer data","url":"https://stock-news.laohu8.com/highlight/detail?id=2603356529","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603356529?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:39","pubTimestamp":1768253996,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Actuate Therapeutics, Inc. ( ($ACTU) ). On January 12, 2026, Actuate Therapeutics reported positive follow-up d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-reports-positive-phase-2-pancreatic-cancer-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-reports-positive-phase-2-pancreatic-cancer-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2603526582","title":"BRIEF-Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526582","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526582?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:06","pubTimestamp":1768251985,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC FilingJan 12  - SEC Filing:ACTUATE THERAPEUTICS INC - REPORTS POSITIVE PHASE 2 TRIAL DATA FOR ELRAGLUSIB - SEC FILINGACTUATE THERAPEUTICS INC - PHASE 2 STUDY SHOWS IMPROVED SURVIVAL WITH ELRAGLUSIB - SEC FILINGSource text: [ID:n0001683168-26-000217]Further company coverage: ACTU.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0RP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2602114543","title":"Actuate Therapeutics says Phase 2 study met primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2602114543","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602114543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:51","pubTimestamp":1768225887,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced that new additional and promising patient survival and biomarker data from treatment with elraglusib for meta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-says-phase-2-study-met-primary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-says-phase-2-study-met-primary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823434740.USD","LU0433182093.SGD","LU2463028550.USD","LU0210536198.USD","SG9999014914.USD","LU2054465674.USD","LU2505996509.AUD","LU2065171402.SGD","LU2360032135.SGD","LU2487616109.SGD","LU0210528500.USD","IE00B775H168.HKD","LU0980610538.SGD","LU1119994496.HKD","LU2746668974.SGD","LU0320765059.SGD","LU2592432038.USD","LU1791710400.SGD","LU0353189763.USD","IE0002270589.USD","LU1564329115.USD","LU0795875086.SGD","LU2347655073.USD","LU1496350502.SGD","LU2403377893.USD","LU1839511570.USD","LU2552382132.HKD","SG9999015945.SGD","LU0985320562.USD","LU0820561909.HKD","LU0345769128.USD","LU2237957902.USD","LU0215105999.USD","LU1992135472.HKD","LU0417517546.SGD","LU1116320901.HKD","IE00B3SWFQ91.USD","IE00B19Z3B42.SGD","IE00BFSS8Q28.SGD","SGXZ31699556.SGD","LU2461242641.AUD","LU1815336760.USD","IE00BQXX3D17.EUR","LU1670627923.USD","LU1914381329.SGD","LU0444973449.USD","LU0211328371.USD","LU2552382058.USD","LU0820561818.USD","SG9999004303.SGD","LU0823434583.USD","LU1861559042.SGD","LU0882574139.USD","LU1670710661.SGD","LU2125154935.USD","LU2065170008.USD","LU1732800096.USD","LU2347655156.SGD","LU0208291251.USD","LU2106854487.HKD","LU1242518857.USD","LU0672654240.SGD","LU0070302665.USD","BK4139","LU0784383803.USD","LU2242650005.HKD","LU0788109477.HKD","LU0476273544.USD","IE000KEQY171.SGD","LU0096362180.USD","LU0528227936.USD","LU1267930730.SGD","IE00BJTD4V19.USD","LU2322448957.HKD","LU2097829019.USD","LU2065171311.SGD","LU2458330243.SGD","LU1803068979.SGD","BK4507","LU1564329628.SGD","LU0795875169.SGD","LU1861558580.USD","IE000W1ABFV2.USD","LU0708995401.HKD","LU1301847155.USD","LU1366192091.USD","LU2420271590.USD","LU1670628061.USD","LU0265550946.USD","LU2602419157.SGD","LU0096364046.USD","LU1670710588.SGD","LU0640476718.USD","LU0683600562.USD","LU0308772762.SGD","LU2764263203.CNY","LU0979878070.USD","IE00BWXC8680.SGD","LU2087621335.USD","LU0553294199.USD","LU2430703095.HKD","IE00BK4W5M84.HKD","LU1074936037.SGD","LU0661504455.SGD","LU2168563687.JPY","LU0320765489.SGD","LU0545039389.USD","LU1066051498.USD","LU0724617625.USD","IE0003U64NQ7.SGD","LU0080751232.USD","LU0823421416.USD","LU2168564149.EUR","BK4588","LU1366333091.USD","LU2552382215.SGD","LU0323591593.USD","SGXZ51526630.SGD","IE0001KFT4U8.USD","LU0878866978.SGD","SG9999014898.SGD","LU0130102774.USD","LU0726765562.USD","LU0466842654.USD","IE00BQXX3F31.USD","LU0690374961.EUR","LU2458330169.SGD","IE00B7KXQ091.USD","LU0157215616.USD","LU2087625088.SGD","SG9999018857.SGD","LU0689472784.USD","BK4585","LU0985489474.SGD","IE00BJLML261.HKD","SG9999002232.USD","LU2360106780.USD","LU0211327993.USD","IE00B4JS1V06.HKD","LU2381873111.SGD","LU1116320737.USD","LU0310799852.SGD","LU2417539215.USD","LU0265550359.USD","SG9999014880.SGD","BK4524","LU0234570918.USD","LU0072462426.USD","LU2272731782.SGD","LU2236285917.USD","LU2473716301.USD","LU1852331112.SGD","LU1564329461.SGD","LU0070217475.USD","LU2264538146.SGD","LU2168564222.USD","LU1571399168.USD","IE00B5949003.HKD","LU1489326972.SGD","LU0154236417.USD","LU1435385759.SGD","IE00BK4W5L77.USD","LU0006306889.USD","LU1201861249.SGD","LU1564329032.USD","LU0068578508.USD","LU1242518931.SGD","LU0949170426.SGD","BK4077","SGXZ23171101.USD","BK4587","LU1551013425.SGD","LU0061474960.USD","LU1974910355.USD","SG9999015978.USD","LU0784384876.USD","IE00BMPRXQ63.HKD","SGXZ81514606.USD","LU0053666078.USD","LU2404859741.USD","IE00B1XK9C88.USD","LU0276348264.USD","SG9999001077.SGD","LU0203345920.USD","IE00BQXX3C00.GBP","LU0348723411.USD","LU0823421333.USD","LU0820562030.AUD","LU0077335932.USD","LU1868836914.USD","LU2322448791.USD","IE00B19Z8W00.USD","LU2756315664.SGD","LU0784385840.USD","GB00BDT5M118.USD","LU0642271901.SGD","LU2404859667.USD","LU1697837992.HKD","LU2247934214.USD","LU1232071149.USD","IE0004445015.USD","LU0097036916.USD","LU2543165471.USD","LU2168564495.EUR","LU2462157665.USD","SG9999015952.SGD","LU0957808578.USD","LU2272731865.HKD","IE0034235303.USD","LU1046421795.USD","LU0345769631.USD","LU0949170772.SGD","IE00B1BXHZ80.USD","LU1732799900.SGD","LU1642822529.SGD","LU0203347892.USD","IE00B19Z8X17.USD","LU1084165304.USD","LU0690374615.EUR","LU2133065610.SGD","IE00BMPRXN33.USD","LU0211331839.USD","LU0203202063.USD","LU0061475181.USD","LU2213496289.HKD","IE00B19Z9505.USD","LU2896262040.SGD","LU2764263039.SGD","LU2317271919.USD","BK4592","IE0009G5SDU7.USD","ACTU","LU2272731600.USD","LU0912757837.SGD","LU1066053197.SGD","LU0964807845.USD","LU0079474960.USD","LU1868836591.USD","LU0444971666.USD","LU2326559502.SGD","IE00BKDWB100.SGD","SG9999014906.USD","LU0106261372.USD","LU1823568750.SGD","LU2430703251.USD","LU0957791311.USD","LU1280957306.USD","IE00B7SZLL34.SGD","LU1674673428.USD","LU1429558221.USD","SG9999018865.SGD","LU1778281490.HKD","LU1868836757.USD","LU1670711123.USD","IE00BJJMRY28.SGD","LU0170899867.USD","LU0198837287.USD","BK4543","HK0000914686.HKD","LU1064131342.USD","LU1917777945.USD","GB00B4LPDJ14.GBP","LU1988902786.USD","IE00BN29S564.USD","LU1035775433.USD","LU2065169927.USD","LU2505996681.GBP","LU0267386448.USD","LU1548497426.USD","IE00B4YYXB79.USD","LU2023250504.SGD","LU2125154778.USD","IE00BJJMRX11.SGD","LU0011850046.USD","LU2361044865.SGD","LU2357305700.SGD","LU0719512351.SGD","LU1127390331.HKD","LU0353189680.USD","SG9999015986.USD","LU0786609619.USD","SG9999017495.SGD","LU1267930490.SGD","LU1699723380.USD","IE000ITXATA3.USD","IE00BFSS7M15.SGD","LU0082616367.USD","LU1316542783.SGD","IE0009356076.USD","IE000YTNTUN2.SGD","LU0316494557.USD","LU0787776722.HKD","LU2265009873.SGD","LU2237957811.SGD","LU2361044949.HKD","LU1868837136.USD","IE00BMPRXR70.SGD","LU0127658192.USD","LU1720051017.SGD","LU0109392836.USD","LU1868837300.USD","LU1069344957.HKD","LU0234572021.USD","LU1815333072.USD","LU1814569148.SGD","LU0256863811.USD","LU0225283273.USD","IE0005OL40V9.USD","LU0943347566.SGD","SGXZ99366536.SGD","LU0889565833.HKD","LU1804176565.USD","LU0738911758.USD","LU1791710582.SGD","LU0056508442.USD","GB00B4QBRK32.GBP","LU0354030511.USD","LU2430703178.SGD","LU0210533765.USD","LU1674673691.USD","LU1153585028.USD","LU2860962120.EUR","LU2023250843.SGD","LU0203201768.USD","LU0149725797.USD","LU2063271972.USD","LU2361045086.USD","LU2168564065.EUR","LU2456880835.USD","LU1718418525.SGD","LU1235294995.USD","SG9999002224.SGD","HK0000914660.USD","LU1551013342.USD","LU2756315318.SGD","LU0256863902.USD","LU2023250330.USD","IE0034235188.USD","IE00BJTD4N35.SGD","LU1629891620.HKD","LU1003077747.HKD","LU1145028129.USD","LU0061474705.USD","LU0648001328.SGD","LU1992135399.USD","LU2250418816.HKD","LU0109391861.USD","LU0784385170.HKD","IE00B19Z3581.USD","LU2746668461.USD","LU1670711040.USD","LU2764262908.HKD","LU0354030438.USD","LU1261432733.SGD","LU2720916845.USD","LU1720051108.HKD","IE0004445239.USD"],"gpt_icon":0},{"id":"2602543313","title":"Actuate Therapeutics Reports Phase 2 Trial Success for Elraglusib in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543313","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543313?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:45","pubTimestamp":1768225512,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc. has announced new data from its Phase 2 clinical trial evaluating elraglusib in combination with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The results were presented in both oral and poster sessions at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium  on January 9, 2026. The study met its primary endpoint, demonstrating a statistically significant improvement in overall survival for patients receiving the elraglusib combination compared to chemotherapy alone. The elraglusib combination reduced the risk of death by 38% compared to gemcitabine/nab-paclitaxel alone, with increased durable survival observed beyond 24 months. As of November 2025, seventeen patients remain alive in the elraglusib combination arm, with three patients surpassing the 24-month survival mark, while no patients remain on chemotherapy alone.Disclaimer: This news brief was created by Public Technologies  using generati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9STHRp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4588","IE00BKPKM429.USD","ACTU","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","NDAQ","SG9999014013.SGD","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2602543575","title":"Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543575","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543575?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:45","pubTimestamp":1768225500,"startTime":"0","endTime":"0","summary":"Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib combinatio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216938/0/en/Actuate-Therapeutics-Reports-Positive-Follow-Up-Data-from-its-Randomized-Controlled-Phase-2-Trial-Demonstrating-Extended-Long-Term-Overall-Survival-Benefit-with-Elraglusib-Plus-Che.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"gpt_icon":0},{"id":"2601800388","title":"Actuate Therapeutics Director Todd Thomson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800388","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601800388?lang=en_us&edition=fundamental","pubTime":"2026-01-08 01:46","pubTimestamp":1767807983,"startTime":"0","endTime":"0","summary":"Todd S. Thomson, Director and 10% Owner of Actuate Therapeutics Inc., along with other reporting beneficial owners, reported a disposal of common shares of Actuate Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL64CDLh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Actuate Therapeutics Director Todd Thomson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2601968813","title":"BRIEF-Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601968813","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601968813?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:24","pubTimestamp":1767709483,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial Jan 6 (Reuters) - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS ANNOUNCES POSITIVE PATIENT OUTCOMES FROM PHASE ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA9RZTWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2601890719","title":"Actuate Therapeutics Reports Positive Phase 1 Results for Elraglusib in Pediatric Ewing Sarcoma and Neuroblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890719","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890719?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:45","pubTimestamp":1767707120,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc. has announced positive results from the phase 1 portion of its phase 1/2 clinical study  evaluating elraglusib, a GSK-3β inhibitor, in pediatric patients with relapsed or refractory cancers. Data from the trial showed two complete metabolic responses in patients with metastatic Ewing sarcoma and one complete response in a patient with metastatic neuroblastoma. Clinical responses and disease control were observed in 15 of 40 patients overall, including 10 of 19 patients treated with elraglusib in combination with cyclophosphamide and topotecan. Based on these results, Actuate plans to advance clinical development of elraglusib for Ewing sarcoma and potentially neuroblastoma, with additional clinical trials expected to begin in 2026. The company has been granted Rare Pediatric Disease Designations from the FDA for both indications. The results have already been presented.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL8PHs12:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","BK4585","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2601818471","title":"Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818471","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818471?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:45","pubTimestamp":1767707100,"startTime":"0","endTime":"0","summary":"Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213650/0/en/Actuate-Therapeutics-Announces-Positive-Patient-Outcomes-from-Phase-1-Trial-in-Difficult-to-Treat-Refractory-Pediatric-Cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4135","BK4567","ACTU","ETS","BK4139","BK4213","LU1093756168.USD","BK4533","EWS","CR","LU2413666426.HKD","IE00B5TLWC47.USD","LU2211817866.USD","PR","SD","MTD","CNS","LU2413666699.HKD","BK4588","LU0347712357.USD","LU1721428933.USD","IE00BFXG0V08.USD","LU1093756325.SGD","BK4232","IE00BYQQ9H92.USD","BK4121","BK4585","BK4161"],"gpt_icon":0},{"id":"2592909049","title":"Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909049","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909049?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:45","pubTimestamp":1766065527,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation. Actuate Therapeutics Inc. has announced that data from its Phase 2 clinical trial in metastatic pancreatic cancer will be featured in both an oral and poster presentation at the ASCO GI 2026 conference. The presentations are scheduled for January 9, 2026. The study evaluates the company’s lead investigational drug, elraglusib, a novel GSK-3β inhibitor targeting molecular pathways involved in tumor growth and resistance to conventional cancer therapies. The results are expected to be presented at the conference and have not yet been disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL4SKPh1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ACTU","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","BK4139","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","BK4112","BK4588"],"gpt_icon":0},{"id":"2591417156","title":"Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2591417156","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591417156?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:45","pubTimestamp":1765806314,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta  inhibitor, in combination with platinum chemotherapy , with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research , show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLtyvkh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","LU0314104364.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","BK4585","SG9999014039.USD","LU2210150020.SGD","NDAQ","ACTU","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2587275846","title":"Actuate Therapeutics Signs $100M Sales Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2587275846","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587275846?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:48","pubTimestamp":1764370127,"startTime":"0","endTime":"0","summary":"An update from Actuate Therapeutics, Inc. ( ($ACTU) ) is now available. On November 28, 2025, Actuate Therapeutics, Inc. entered into an At the Mar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-signs-100m-sales-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-signs-100m-sales-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU"],"gpt_icon":0},{"id":"2587301758","title":"BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587301758","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587301758?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:28","pubTimestamp":1764368918,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC FilingNov 28  - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS INC - MAY SELL COMMON STOCK UP TO $100 MILLION - SEC FILINGACTUATE THERAPEUTICS INC - ENTERS AT THE MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY AND CRAIG-HALLUM - SEC FILINGFurther company coverage: ACTU.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40LI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2587875889","title":"Actuate Therapeutics Inc - Enters at the Market Issuance Sales Agreement With B. Riley and Craig-Hallum - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587875889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587875889?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:23","pubTimestamp":1764368587,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40LI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}